Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 27 , ISSUE 8 ( August, 2023 ) > List of Articles


Modification of Initial Empirical Antibiotic Prescription and its Impact on Patient Outcome: Experience of an Indian Intensive Care Unit

Supradip Ghosh, Amandeep Singh, Aditya Lyall

Keywords : Antibiotic stewardship, Culture-negative sepsis, De-escalation, Empirical antibiotic

Citation Information : Ghosh S, Singh A, Lyall A. Modification of Initial Empirical Antibiotic Prescription and its Impact on Patient Outcome: Experience of an Indian Intensive Care Unit. Indian J Crit Care Med 2023; 27 (8):583-589.

DOI: 10.5005/jp-journals-10071-24505

License: CC BY-NC 4.0

Published Online: 31-07-2023

Copyright Statement:  Copyright © 2023; The Author(s).


Introduction: Data on the overall impact of antibiotic modification following initial empiric prescription in both culture-positive and culture-negative critically ill patients are exiguous. Materials and methods: In a retrospective analysis of “ANT-CRITIC” study, we classified ICU patients receiving empirical antibiotics who remained in the ICU for >72 hours or till availability of culture results (whichever is longer) into five groups based on culture results and antibiotic modification: negative culture, no change (group I), positive culture, no change (group II), positive culture, de-escalation (group III), positive culture, escalation (group IV) and negative culture, antibiotic modification (group V). Baseline variables and clinical outcomes were compared. Logistic regression analysis was performed to look for independent variables associated with mortality. Results: 276 prescription episodes were analyzed. Group II was associated with worsening organ dysfunction at 72 hours, lower clinical cure rate at day 7, and higher hospital mortality. There was an independent association between group II prescription and hospital mortality [adjusted OR 2.774 (CI 1.178–6.533), p = 0.02]. Group III received longer duration of antibiotic (mean duration = 8.27 ± 4.11 days, median duration = 7 days [IQR 5–11]). Conclusion: Outcomes of critically ill infected patients differ significantly when they are classified based on culture result and antibiotic modification pattern.

  1. Ghosh S, Salhotra R, Singh A, Lyall A, Arora G, Kumar N, et al. New antibiotic prescription pattern in critically ill patients (“ANT-CRITIC”): Prospective observational study from an Indian intensive care unit. Indian J Crit Care Med 2022;26(12):1275–1284. DOI: 10.5005/jp-journals-10071-24366.
  2. Ghosh S, Singh A. Principle of antimicrobial uses. In: Mehta Y, Sharma J, Mehta C (Editors). Textbook of Critical Care, 2nd edition. New Delhi: Jaypee Brothers Medical Publishers, 2022, pp. 775–782.
  3. Teshome BF, Vouri SM, Hampton N, Kollef MH, Micek ST. Duration of exposure to antipseudomonal β-lactam antibiotics in the critically ill and development of new resistance. Pharmacotherapy 2019;39(3):261–270. DOI: 10.1002/phar.2201.
  4. Tabah A, Bassetti M, Kollef MH, Zahar JR, Paiva JA, Timsit JF, et al. Antimicrobial de-escalation in critically ill patients: A position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIP). Intensive Care Med 2020;46(2):245–265. DOI: 10.1007/s00134-019-05866-w.
  5. Tabah A, Cotta MO, Garnacho-Montero J, Schouten J, Roberts JA, Lipman J, et al. A systematic review of the definitions, determinants, and clinical outcomes of antimicrobial de-escalation in the intensive care unit. Clin Infect Dis 2016;62(8):1009–1017. DOI: 10.1093/cid/civ1199.
  6. De Bus L, Depuydt P, Steen J, Dhaese S, De Smet K, Tabah A, et al. Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure: The DIANA study. Intensive Care Med 2020;46(7): 1404–1417. DOI: 10.1007/s00134-020-06111-5.
  7. Leone M, Bechis C, Baumstarck K, Lefrant JY, Albanèse J, Jaber S, et al. De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: A multicenter non-blinded randomized noninferiority trial. Intensive Care Med 2014;40(10):1399–1408. DOI: 10.1007/s00134-014-3411-8.
  8. Lew KY, Ng TM, Tan M, Tan SH, Lew EL, Ling LM, et al. Safety and clinical outcomes of carbapenem de-escalation as part of an antimicrobial stewardship programme in an ESBL-endemic setting. J Antimicrob Chemother 2015;70(4):1219–1225. DOI: 10.1093/jac/dku479.
  9. De Bus L, Denys W, Catteeuw J, Gadeyne B, Vermeulen K, Boelens J, et al. Impact of de-escalation of beta-lactam antibiotics on the emergence of antibiotic resistance in ICU patients: A retrospective observational study. Intensive Care Med 2016;42(6):1029–1039. DOI: 10.1007/s00134-016-4301-z.
  10. Kitsios GD, Morris A, McVerry BJ. Antibiotic de-escalation: Observational causal inference and culture dependence. Intensive Care Med 2016;42(10):1647–1648. DOI: 10.1007/s00134-016-4443-z.
  11. Gupta S, Sakhuja A, Kumar G, McGrath E, Nanchal RS, Kashani KB. Culture-negative severe sepsis: Nationwide trends and outcomes. Chest 2016;150(6):1251–1259. DOI: 10.1016/j.chest.2016.08.1460.
  12. Labelle AJ, Arnold H, Reichley RM, Micek ST, Kollef MH. A comparison of culture-positive and culture-negative health-care-associated pneumonia. Chest 2010;137(5):1130–1137. DOI: 10.1378/chest.09-1652.
  13. Kim JS, Kim YJ, Kim WY. Characteristics and clinical outcomes of culture-negative and culture-positive septic shock: A single-center retrospective cohort study. Crit Care 2021;25:11. DOI:
  14. Bouadma L, Luyt CE, Tubach F, Cracco C, Alvarez A, Schwebel C, et al. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): A multicentre randomised controlled trial. Lancet 2010;375(9713):463–474. DOI: 10.1016/S0140-6736(09)61879-1.
  15. Madaras-Kelly K, Jones M, Remington R, Hill N, Huttner B, Samore M. Development of an antibiotic spectrum score based on veterans affairs culture and susceptibility data for the purpose of measuring antibiotic de-escalation: A modified Delphi approach. Infect Control Hosp Epidemiol 2014;35(9):1103–1113. DOI: 10.1086/677633.
  16. Bassetti M, Rello J, Blasi F, Goossens H, Sotgiu G, Tavoschi L, et al. Int J Antimicrob Agents 2020;56(6):106184. DOI: 10.1016/j.ijantimicag.2020.106184.
  17. De Waele JJ, Schouten J, Beovic B, Tabah A, Leone M. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: No simple answers to simple questions – A viewpoint of experts. Intensive Care Med 2020;46(2):236–244. DOI: 10.1007/s00134-019-05871-z.
  18. de Jong E, van Oers JA, Beishuizen A, Vos P, Vermeijden WJ, Haas LE, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: A randomised, controlled, open-label trial. Lancet Infect Dis 2016;16(7):819–827. DOI: 10.1016/S1473-3099(16)00053-0.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.